Navigation Links
AMDL Wins Chinese Military Supply Agreement for Its Domperidone Product for up to $6.6 Million

TUSTIN, Calif., Jan. 30 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, through its wholly owned subsidiary Jade Pharmaceutical Inc., (JPI) is an international biopharma company that, together with JPI, engages in the development, manufacture and marketing of proprietary pharmaceutical, health care and diagnostic products. The Company announced today that JPI's subsidiary, JJB, won a supply contract for the delivery of Domperidone to the Chinese Military through HaiHong Pharmaceutical E-Commerce Account Settlement Service Ltd., the Chinese agents for the Chinese Military Planned Drugs Online Focused Purchase Campaign.

Frank Zheng, Managing Director of JPI, stated that "this distribution agreement will position JJB to become the premier supplier for the Military Strategic Drug Reserve. It is estimated that Domperidone could realize sales of approximately $6.6 million in 2008 through this individual contract. JPI is also promoting other JJB and YYB products through this supply channel and is confident that additional products from JJB and YYB will also win bids."

Mr. Gary Dreher, CEO of AMDL noted that "this new distribution channel illustrates JPI's ability to execute on its 2008 business plan and significantly improves JPI's ability to grow its sales in 2008 and beyond."

About Domperidone: Domperidone is an important medicine for treating nausea and vomiting. JPI's generic version of this product is significantly lower priced than other China pharma competitors.

About Jade Pharmaceutical Inc.: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, JPI currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards.

About AMDL: More information about AMDL and its products can be obtained at

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, and actual circumstances, events or results may differ materially from those projected in such forward-looking statements. The Company cautions readers not to place undue reliance on any forward-looking statements. The Company does not undertake, and specifically disclaims any obligation, to update or revise such statements to reflect new circumstances or unanticipated events as they occur.

Contact: AMDL, Inc.

Mr. Paul Knopick

AMDL Investor Relations

Direct Line: 949.707.5365

VoiceMail: 714.505.4460

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
2. ARIUS to present at Chinese Global Financial Forum
3. AMDLs Chinese Subsidiary Wins Key Brand Excellence Award for Anti-Aging Treatment
4. DuPont Joint Venture with Chinese Biotech Firm Strengthens Gene Discovery Research Efforts
5. Aida Receives Chinese Government Innovation Award
6. China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site
7. Vical Presentation at Military Pandemic Influenza Workshop
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
10. 2007 Global Survey Identifies Characteristics of Supply Chain Leaders
11. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm ... Mold) microbial test has received AOAC Research Institute approval 061601. , “This is ... last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The ...
(Date:6/23/2016)... June 23, 2016   EpiBiome , a precision ... million in debt financing from Silicon Valley Bank (SVB). ... and to advance its drug development efforts, as well ... "SVB has been an incredible strategic partner ... a traditional bank would provide," said Dr. Aeron ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
Breaking Biology Technology:
(Date:5/12/2016)... , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):